Breast cancer cells interacting with patient-specific MSCs treated with DMSO showed an increase in genes associated with cell migration (e.g., VIM, CDH1, FN1, ZEB1, MMP2, SPARC), tissue morphogenesis (e.g., CCN2, TWIST1, CDH11, DCN, ESRP1) and epithelial to mesenchymal transition (e.g., AXIN2, BMP2, COL1A1, CTNNB1, EZH2, FOXC1, JAG1, MARK1, LEF1, NOTCH1), compared to MCF7 cells co-cultured with patient-derived MSCs treated with TGFβ inhibitor (Fig 6F). This evidence concerns the gene ESRP1 and breast cancer.